Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Fexuprazan and DWC202005 in Healthy Volunteers
NCT04328766Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fexuprazan and DWC202005 in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area under the plasma drug concentration-time curve, Peak Plasma Concentration and 1 more. Started Sep 2020; status: completed.
02
Drugs
fexuprazanDWC202005
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04328766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328766.